http://www.biospace.comBioSpace RSS GeneratorWed, 22 May 2013 07:08:08 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130516006327&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Euronext Paris: TNG)(Paris:TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs...Tue, 21 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297086&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Merck Increases Its Commitment to MS Ventures to 100 million</font></b><br><br>Darmstadt, Germany, May 16, 2013 - Merck announced today that it will increase its commitment to its strategic...Fri, 17 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130516006532&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>LYON, France & ILLKIRCH-GRAFFENSTADEN, France--(BUSINESS WIRE)--ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M from...Fri, 17 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=295710&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>MONT-SAINT GUIBERT, Belgium, May 8, 2013 /PRNewswire/ -- The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive...Wed, 08 May 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130502_2Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>by Richard Daverman, PhD</p><p>May 2, 2013 -- Zhejiang Huahai Pharma will offer 63.3 million shares at a price of 12.25 RMB each, raising 775 million RMB ($126 million) in a secondary offering. It...Fri, 03 May 2013 12:00:00 AM GMThttp://www.bizjournals.com/washington/blog/techflash/2013/05/intrexon-raises-150-million-mega-round.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Synthetic biology company Intrexon Corp., which has major operations in Germantown, just announced a $150 million mega-financing from both new investors and affiliates of company's own chairman and CEO...Thu, 02 May 2013 12:00:00 AM GMTStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>DUBLIN--(BUSINESS WIRE)--Opsona Therapeutics Limited (Opsona), the innate immune drug development company, today announced that it has raised 33 million (US $ 43 million) in an oversubscribed Series C financing...Mon, 29 Apr 2013 12:00:00 AM GMThttp://www.swissinfo.ch/eng/business/Novartis_invests_in_factory_once_slated_to_close.html?cid=35636414Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Swiss pharmaceutical group Novartis has announced it will invest an additional CHF150 million ($160 million) until 2020 into bolstering its production site near Geneva, 18 months after it had threatened to...Fri, 26 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294324&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>MECHELEN, BELGIUM--(Marketwired - April 24, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG)announced today that it has raised EUR53.9 million through a privateplacement...Thu, 25 Apr 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130422_1by Richard Daverman, PhD</p><p>April 22, 2013 -- Syros Pharmaceuticals, a Boston area startup, raised $30 million to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding, which was led by ARCH Venture Partners and Flagship Ventures. More details....</p><p>Stock Symbol...Tue, 23 Apr 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130419_1by Richard Daverman, PhD</p><p>April 19. 2013 -- The Zongyi Group of China has invested $8.6 million in ContraFect Corporation, a New York City-area biotech that is developing biotech antibiotics. ContraFect is focused on the use of monoclonal antibodies and lysins as solutions for difficult-to-treat infectious diseases. The company said the new capital it raised $9.5 million in the round would...Fri, 19 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293311&full=1April 16, 2013 Auris Medical secures CHF 47.1 mn Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development.</p><p>Auris Medical, a company dedicated to the development of novel therapeutics for the treatment of inner ear disorders, announced today the completion of a CHF 47.1 million1 Series C financing...Tue, 16 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293305&full=1YONKERSContraFect Corporation announced today that the Zongyi Group of China has invested $8.6 million in the company as part of a $9.5-million financing. Meanwhile, the representative nominated by the Zongyi Group has been elected to ContraFects Board of Directors.</p><p>We are excited that we have attracted an investment from the Zongyi Group, stated Robert Nowinski, founder and chief executive...Mon, 15 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292702&full=1London, UK, April 8, 2013 / B3C newswire / - Canbex Therapeutics Ltd announced today that it has completed a 2.1m ($3.2m) fundraising round that will enable the Company to complete the early development of its lead candidate for the treatment of spasticity in multiple sclerosis (MS). Merck Serono Ventures, the venture capital arm of Merck Serono, led the financing for this round.</p><p>The goal...Mon, 08 Apr 2013 12:00:00 AM GMThttp://www.marketwatch.com/story/sanofi-to-invest-75m-in-new-vietnam-pharma-plant-2013-03-29Sanofi (SAN), Frances biggest drugmaker, will start building a $75 million plant in Vietnam as rising income and urbanization bolsters demand for health care in Asia. The company, which has been in the country of nearly 90 million for more than 50 years, will produce at an initial capacity of 90 million units per year at the new facility when it starts operations by the end of 2015 and may later extend...Fri, 29 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291655&full=1Darmstadt, March 27, 2013 - Merck announced today the successful closing of a 2 billion syndicated loan facility. The syndicated loan was underwritten by an international group of banks and has a tenor of five years with extension options for a total tenor of seven years. It replaces an existing, unused 2 billion loan facility that would have expired in 2014. The early renewal of the syndicated...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291660&full=1<div id"releaseBody"><p>MELBOURNE, AUSTRALIA--(Marketwire - March 27, 2013) - <b> Prana Biotechnology </b>(NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPRAN">PRAN</a>) (ASX: PBT), today announced that it has secured funding of A$7 million through a placement of approximately 35.9 million fully paid ordinary shares at a price of A$0.195 per share (equivalent to approximately...Wed, 27 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291583&full=1Nijmegen/Utrecht, the Netherlands, March 26, 2013 / B3C newswire / InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investors participating in this round include the Innovation & Investment Fund Gelderland, managed by PPM Oost and several business angels....Tue, 26 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291224&full=1<div id"releaseBody"><p>COLOGNE, GERMANY--(Marketwire - March 21, 2013) - CryoTherapeutics GmbH (CryoTherapeutics), the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease, announced today that it has completed a second closing of its Series A financing round, with Peppermint VenturePartners (PVP) via its new Charit&#233; Biomedical Fund joining...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291003&full=1Cologne, Germany, March 18, 2013. Today, Direvo Industrial Biotechnology GmbH (Direvo) announced the successful closure of a financing round of three and a half million Euro to fund the sustainable growth of the company.</p><p>All current major investors participated in this third financing round since the founding of Direvo, a spin-off from Direvo Biotech AG, in the year 2008. The capital will...Tue, 19 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290478&full=1MELBOURNE, Australia; 14 March 2013: Regenerative medicine company Mesoblast Limited (ASX:MSB, USOTC:MBLTY) today announced that it has completed a private placement of its shares, raising A$170 million. Mesoblast now has cash reserves of approximately A$332 million. </p><p> Under the placement, 26,970,979 fully paid ordinary shares were issued at A$6.30 per share, a discount of ...Thu, 14 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290450&full=1Dijon and Paris, France, March 11, 2013 - In the presence of French president, Francois Hollande, Francois Drouin, OSEO's CEO and vice-president of the BPI (Banque Publique d'Investissement), announced to Philippe Genne, Oncodesign's CEO and leader of the IMODI (Innovative MODels Initiative), that this project will receive EUR 13.4 million in funding under the French Government's Investing for the...Wed, 13 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289984&full=1London: strictly embargoed until: 7.30 am UK time on 11 March 2013 Progenitor Labs Ltd (Progenitor) has announced that it has raised 4 million ($5.8 million) in seed financing from SR Ones UK Fund.</p><p>Progenitor is a pioneering regenerative medicine company that develops drugs to regenerate specific tissues of the human body in response to injury, disease or ageing. Development of small...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130307_1by Richard Daverman, PhD</p><p>March 7, 2013 -- According to reports, Sinopharm Holdings, one of Chinas big-three drug distributors, will issue 4 billion RMB ($640 million) five-year corporate bonds on the Shanghai Stock Exchange. The purpose? The company declared only a not-particularly-specific need to replenish working capital. Can we expect the transaction to spark new M&A activity in China...Thu, 07 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289596&full=1<div id"releaseBody"><p>LUND, SWEDEN--(Marketwire - March 06, 2013) - Active Biotech (NASDAQ OMX NORDIC: ACTI) todayannounces that the company's Board of Directors has, based on the 2012annualgeneral meeting's authorization, resolved to issue in total 6,000,000 newsharesin Active Biotech to Investor AB (publ).<p>The shares are issued at a subscription price of SEK 45 per share...Wed, 06 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289412&full=1TORONTO and SINGAPORE , March 4, 2013 /CNW/ - TauRx Pharmaceuticals Ltd. ("TauRx") announced today the receipt of an equity investment of USD10.5m from Dundee Corporation of Toronto ("Dundee"). The investment will be used by TauRx primarily to support the on-going program of three Phase 3 clinical trials of LMTX, its novel compound currently in development as a disease-modifying treatment for Alzheimer...Tue, 05 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289362&full=1March 3rd, 2013 Utrecht, The Netherlands -- Today, Crossbeta Biosciences announced that it has successfully secured funding to execute its plans for the next years. This financing round is based on investments by new as well as existing shareholders and includes an Innovation Grant from AgentschapNL. The proceeds will be used to further advance Crossbetas drug screening technology platform in several...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288990&full=1<div id"releaseBody"><p>GHENT, BELGIUM--(Marketwire - February 28, 2013) - <b> Ablynx </b>(EURONEXT BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies&#174;, announces today that it has raised EUR 31.5 million through a private placement of new shares via an accelerated bookbuilding procedure announced on Wednesday 27 February 2013 after the market...Thu, 28 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288944&full=1Naarden, The Netherlands, 28 February 2013 Dezima Pharma (Dezima), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that is has raised a total of 14.2m ($18.6m ) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001(previously TA-8995) and to develop additional earlier-stage dyslipidemia assets.</p...Thu, 28 Feb 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130227by Richard Daverman, PhD</p><p>February 27, 2013 -- OrbiMed Advisors is raising $500 million for its second Asia healthcare private equity fund, which will be invested mainly in China and India. Thats up from $300 million rumored as recently as last fall. The company expects to close Asia Partners II later this year, just about the time it will have its $188 million Asia Partners I fund fully...Wed, 27 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288614&full=1OXFORD, England, February 26, 2013 /PRNewswire/ -- Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a 14.0 million ($21.4 million) investment round. The fundraising was led by funds managed by Invesco Perpetual and supported by existing investors. To date, Glide Pharma has successfully...Tue, 26 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288231&full=1YAVNE, Israel--(BUSINESS WIRE)-- Avraham Pharmaceuticals Ltd. announced today that Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries (CBI.TA) and the Technion Research and Development Foundation Ltd. (TRDF) invested an additional $ 5.7 million in the Company. Following the current investment round, Yissum...Thu, 21 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287698&full=1February 14, 2013 -- The collaborative project PharmaSea will bring European researchers to some of the deepest, coldest and hottest places on the planet. Scientists from the UK, Belgium, Norway, Spain, Ireland, Germany, Italy, Switzerland and Denmark will work together to collect and screen samples of mud and sediment from huge, previously untapped, oceanic trenches. The large-scale, four-year project...Thu, 14 Feb 2013 12:00:00 AM GMThttp://www.siliconrepublic.com/careers/item/31451-boost-for-genzymes/Global healthcare giant Sanofi says it will invest 44m to expand on the manufacture of its insulin products at the Genzyme biotech plant in Waterford where some 500 people are employed. Subject to regulatory approvals, commercial production of Lantus, the No 1 insulin brand at Waterford, should commence in 2016. The IDA-supported investment comes on the heels of a major 150m investment announced...Wed, 13 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287245&full=1OXFORD & NEWCASTLE, United Kingdom--(BUSINESS WIRE)-- Drug discovery and development company e-Therapeutics plc (ETX.L) proposes to raise GBP 40 million (approximately GBP 39 million net) through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4% to the closing mid-market price on the last dealing day before this announcement...Mon, 11 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=286966&full=1<div id"releaseBody"><p>LYON, FRANCE--(Marketwire - February 07, 2013) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid983150&attachid2222958">Flamel Technologies website</a></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid983150&attachid222298...Thu, 07 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=286358&full=131 January 2013 - London, UK Verona Pharma plc announces a placing (the Placing) of approximately 29.0 million Ordinary Shares of 0.1 pence in the capital of the Company (Shares) at 4 pence each (the Placing Price) to raise approximately 1.1 million before expenses. The Board also announces that the Company has entered into a 5.0 million equity financing facility (EFF) with Darwin...Thu, 31 Jan 2013 12:00:00 AM GMThttp://www.bbc.co.uk/news/uk-scotland-scotland-business-21131627A 50m venture capital fund focusing on early-stage life science and health technology companies has been launched in Scotland. Rock Spring Ventures said it had already secured commitments worth more than 25m from a range of investors. Backers include the universities of Glasgow, Edinburgh and Aberdeen. The fund aims to provide capital to the most promising life science technologies, including those...Tue, 22 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=285389&full=1Paris, January 21, 2013 Truffle Capital, a key European player in private equity, the 1st FCPI (retail funds) manager in terms of performance1 and the 2nd in terms of market share2, makes an assessment for 2012. </p><p>An increase in annual fundraising </p><p>Truffle Capital raised 50 million in 2012 through FCPI, which is 25% more than the previous year, a remarkable...Tue, 22 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284909&full=1<div id"releaseBody"><p>LEIDEN, THE NETHERLANDS--(Marketwire - January 16, 2013) - Biotech company Pharming Group NV("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced thatit hasentered into a financing of EUR16.35 million (EUR 15.3 million netproceeds aftersubtraction of transaction fees and a 2% issuers discount) by meansof aconvertible bond with...Wed, 16 Jan 2013 12:00:00 AM GMThttp://wraltechwire.com/gsk-partner-stock-plunges-after-drug-failure/11961707/GlaxoSmithKline is looking to fatten its drug pipeline through another venture capital investment with a $50 million commitment to a California fund. The drug giant on Wednesday said it would invest in the $250 million Sanderling Biotech Venture Fund. The fund will be managed out of San Mateo, Calif. The commitment is one of several made by GSK (NYS: GSK) to several funds focused on helping emerging...Thu, 10 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284390&full=1Lausanne January 9th, 2013 Debiopharm Group (Debiopharm) and Spinomix SA, a Swiss company advancing molecular diagnostic technologies, announced the closing of a Series A equity investment of $ 3 Million. The financing round was led by Debiopharm Group. Significant participation and support is being provided by existing investors and a private US investor group with proven entrepreneurial experience...Wed, 09 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284275&full=1LAVAL, QUEBEC--(Marketwire - Jan 8, 2013) - ProMetic Life Sciences Inc. (PLI.TO) ("ProMetic" or the "Corporation") announced today that it has finalized the $10 million strategic equity investment in ProMetic by Shenzhen Hepalink Pharmaceutical Co., Ltd pursuant to the terms and conditions previously disclosed on October 16, 2012.</p><p>"The funds received will enable the execution of various strategic...Wed, 09 Jan 2013 12:00:00 AM GMThttp://www.independent.ie/business/irish/44m-boost-for-mylans-irish-arm-3346419.htmlThe Irish arm of international drug firm Mylan, which is boosting its operations in Ireland with the creation of up to 500 jobs, has received a 44m cash boost from one of its Luxembourg units. US-headquartered Mylan announced last year that it was initiating a 380m expansion of its Irish activities, creating the new jobs in Galway and Dublin by 2016. About 220 of the new jobs are to be created in...Tue, 08 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284070&full=1Petach Tikva, Israel, January 7, 2013. PolyPid Ltd., a developer of innovative drug carriers, today announced that it has raised $2.4 million in a third round of financing from existing and new investors, at a company post-money valuation of $17.4 million.</p><p>PolyPid's flagship platform (also named PolyPid technology), is a new, groundbreaking family of drug carriers, based on an innovative...Mon, 07 Jan 2013 12:00:00 AM GMThttp://www.efinancialnews.com/digest/2013-01-03/wellcome-trust-boosts-exposure-to-higher-growth-countries-at-expense-of-ukThe Wellcome Trust, the worlds second-largest biomedical charity, said it started an investment arm with 200 million pounds ($326 million) of initial capital to back biotechnology startups. The Syncona Partners LLP unit will support new businesses in the medical-device, therapeutics, diagnostics and information-technology industries, London-based Wellcome said today in a statement. Long-term investments...Fri, 04 Jan 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130103006030&newsLang=enPARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the signature of an assurance prospection agreement with Coface granting a guarantee to finance its export activities. Thu, 03 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=283014&full=1STOCKHOLM December 21, 2012. Karolinska Development AB announced today that a syndicate led by the life science investor Rosetta Capital Limited (Rosetta) will acquire a minority share in Karolinska Developments holdings in 13 of its 25 portfolio companies for SEK 220 million. A conference call will be held today at 3.00pm CET. For the purpose of the transaction, Karolinska Development will transfer...Fri, 21 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282577&full=1Lyon, France, December 18, 2012 - Poxel SA announces today, that it has raised 13 million (USD 17 million) in a Series B round. The financing was led by Edmond de Rothschild Investment Partners (EdRIP) and included all existing investors: InnoBio fund managed by CDC Entreprises within FSI France Investment program; and Omnes Capital (formerly Crdit Agricole Private Equity). A significant part of...Tue, 18 Dec 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121215by Richard Daverman, PhD and Henry Ye</p><p>December 14, 2012 -- Sinopharm (China National Pharmaceutical Group) and China Development Bank recently signed a 40 billion RMB ($6.4 billion) agreement that will help Sinopharm and Chinas pharma industry as a whole develop on many fronts. CDB will supply the investment in a combination of investment, loans, debt, rent and other financial services...Tue, 18 Dec 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121215by Richard Daverman, PhD and Henry Ye</p><p>December 14, 2012 -- Sinopharm (China National Pharmaceutical Group) and China Development Bank recently signed a 40 billion RMB ($6.4 billion) agreement that will help Sinopharm and Chinas pharma industry as a whole develop on many fronts. CDB will supply the investment in a combination of investment, loans, debt, rent and other financial services...Thu, 13 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282070&full=1NEW YORK, Dec. 12, 2012 /PRNewswire-iReach/ -- River Vision Development Corp. today announced the completion of a Series A financing, raising $17 million for the development of a novel protein therapy, RV 001, for the treatment of Graves' Orbitopathy (GO). </p><p>GO is a condition afflicting a proportion of Graves' Disease patients, in which an autoimmune response is mounted against tissues behind...Wed, 12 Dec 2012 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2012/12/12/511006/0/en/Zealand-Pharma-A-S-Financial-Calendar-for-2013.htmlCopenhagen, 2012-12-12 10:40 CET (GLOBE NEWSWIRE) -- Zealand Pharma (NASDAQ OMX Copenhagen: ZEAL) announces the following dates for the companys planned financial reporting in 2013:Wed, 12 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281888&full=1Paris. December 11, 2012. Sofinnova Partners today secures its market leading position in Europe with the successful raising of 240 M ($312 M) for its seventh venture capital fund exclusively dedicated to the life sciences.</p><p>In light of the challenging climate for fundraising, the 240 M sum is a significant achievement. This new fund has attracted major institutional investors, predominantly...Tue, 11 Dec 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121210005069&newsLang=enCAMBRIDGE, England--(BUSINESS WIRE)--Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of 3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform. Current investors, Atlas Venture, Novartis Venture Fund, SR One...Mon, 10 Dec 2012 12:00:00 AM GMThttp://www.foxnews.com/health/2012/12/06/european-stem-cell-bank-aims-to-speed-drug-development/Drug companies and universities are spending 55.6 million euros ($72.7 million) to develop a bank of stem cells to use in testing potential treatments for hard-to- treat diseases. The effort, known as Stembancc and managed by the University of Oxford in England, will focus on generating 1,500 induced pluripotent stem cell lines, researchers said at a London news conference. The cells will be used by...Thu, 06 Dec 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20121206005828&newsLang=enTEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE:RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million. The proceeds will be used to advance the Companys late...Thu, 06 Dec 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/11/29/safrica-drugs-idUSL5E8MT88Q20121129?type=companyNews&feedType=RSS&feedName=companyNews&rpc=43South Africa on Thursday awarded a $667 million contract to supply life-prolonging HIV medicine to 12 international and domestic firms, to deal with its biggest health problem. Companies that include Aspen Pharmacare, Abbott Laboratories and Adcock Ingram would share the contract, the health department said. The 5.9 billion rand ($667 million) contract, effective from April next year, aims to increase...Thu, 29 Nov 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/11/26/gskconsumer-shares-idUSL4N0960QE20121126GlaxoSmithKline Plc plans to spend more than $1 billion to raise stakes in its Indian and Nigerian consumer healthcare arms, as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health footprint. The deals are the latest of several by GSK, which is reducing its reliance on traditional regulated markets in Western economies where sales are slowing. GSK said on Monday...Tue, 27 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=280456&full=1Melbourne, Australia; Thursday 22 November 2012: Starpharma (ASX:SPL; OTCQX:SPHRY) today announced that following a submission to AusIndustry, it is eligible to receive approximately $6 million cash in R&D tax incentive for overseas R&D activities. </p><p>Starpharma made a submission for an advance finding in relation to VivaGel activities in June 2012, and AusIndustry has today notified the...Mon, 26 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=280252&full=1SINGAPORE and KUALA LUMPUR , Malaysia , Nov. 20, 2012 /CNW/ - TauRx Pharmaceuticals Ltd. ("TauRx") announced today the receipt of a further equity investment of US$31.5m from Genting Management ( Singapore ) Pte. Ltd. ("GMS"), a wholly owned subsidiary of Genting Berhad. The amount represents the first tranche of a total investment of US$111.8m by GMS in TauRx in exchange for a 20% equity stake in...Tue, 20 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=280242&full=1Amsterdam, The Netherlands, November 20, 2012 / B3C newswire / - Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has raised EUR 10 million in an equity financing round. This round was led by the Company's largest shareholder LSP (Life Sciences Partners) and supported by a large investment from DFJ-Esprit. Other investors...Tue, 20 Nov 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121116Suzhou, China, November 16, 2012 / B3C newswire / - Innovent Biologics, Inc., a company dedicated to the development and manufacturing of monoclonal antibodies to be marketed in the rapidly growing China market and elsewhere around the world, has raised $25 Million in a Series B financing to put toward the continued expansion of its pipeline and manufacturing capabilities. The money comes from Lilly...Fri, 16 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=279310&full=1Copenhagen, Denmark 12 November, 2012 BioGasol ApS, the renewable energy company announced today that it has raised 5 million in new equity financing and received a confirmation of 10 million grant allocation from The Energy Technology Development and Demonstration Program (EUDP), part of the Danish Energy Agency. </p><p>BioGasol has created an innovative pre-treatment reactor design for...Mon, 12 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=279425&full=1<div class"xn-content"><span></span><span></span><span><p><span><span class"xn-location">JERUSALEM</span></span>, Nov.12, 2012 /PRNewswire/ --Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, <span class"xn-location">Israel</span>'s foremost medical research center...Fri, 09 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20121107005631&newsLang=enALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that they have entered into a share purchase agreement through which BioTime agreed to purchase 87,456 Cell Cure ordinary shares in exchange for 906,735 BioTime common shares. As a result of the share purchase, BioTime will own, directly and through...Wed, 07 Nov 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121105_1by Richard Daverman, PhD</p><p>November 5, 2012 -- Vivo Ventures, the California-China healthcare venture capital company, is the lead investor in a 190 million RMB ($30 million) funding round for Shanghai Jingfeng Pharmaceutical Co., according to Venture Wire. In January, Vivo closed Vivo Ventures VII, a $375 million fund. It pledged to allocate 45% of that to China life science companies. Founded...Tue, 06 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=278233&full=1CANTERBURY, England, Nov 05, 2012 (BUSINESS WIRE) -- Recently founded Ziarco, a clinical-stage biotechnology company focused on the development of first-in-class therapeutics targeting inflammatory and allergic diseases, announced today the closing of an initial $6 million (GBP3.75 million) tranche of Series A financing totalling $27 million (GBP16.8 million). The round was led by Biotechnology Value...Mon, 05 Nov 2012 12:00:00 AM GMThttp://www.btimes.com.my/Current_News/BTIMES/articles/20121105154950/Article/index_htmlMalaysia is currently in consideration by Novartis, the world's second largest pharmaceutical company, as a potential site for a healthcare biotechnology investment. In a statement today, Malaysian Biotechnology Corp (Biotech) said Novartis has continued to highlight its partnership with the Sarawak Biodiversity Centre to develop drug compound leads from microbial natural products. "As a further boost...Mon, 05 Nov 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-11-01/UK_science_gains_%C2%A31bn_in_funding.aspxThe UK Government has given a 1 billion cash boost for seven new projects in science and research.<br><br>The new projects double the number of winning bids from the UK Research Partnership Investment Fund to 14. The RPIF which was launched in May this year allocates all funding across two rounds with the support of government and industry.Fri, 02 Nov 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/117634/pound7-million-funding-for-mrc-astrazeneca-compound-collaboration.htmlBritish academic researchers have secured 7 million pounds ($11 million) of funding from the country's Medical Research Council (MRC) to investigate a range of potential new drugs made available free-of-charge by AstraZeneca.<br><br>The move is the latest example of how the pharmaceutical industry is experimenting with new research models involving greater collaboration with external partners.Thu, 01 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=276870&full=1REHOVOTH, Israel--(BUSINESS WIRE)-- Pharma Two B Ltd., a privately held company focused on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, announced that it has completed its second round of financing and has raised $8 million.</p><p>Financing will be used to continue the development of the company's Fixed-Dose-Combination product for the...Tue, 23 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275627&full=1Pompey, France, October 10, 2012 - Novasep, a leading provider of purification-based manufacturing solutions for life science molecules, announces today an investment of EUR 30 million to build in Europe what will be the world's largest chromatography plant used for the production of a large volume commercial API (active pharmaceutical ingredient).</p><p>The plant will be built on Novasep's existing...Wed, 10 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275314&full=1HEIDELBERG, Germany--(BUSINESS WIRE)-- Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of EUR 15.5 million. The proceeds from this transaction will be used to fund the clinical development of Affimed's therapeutic pipeline that consists of two TandAb products, AFM11 and AFM13. AFM13, a CD30/CD16A TandAb is currently...Mon, 08 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274883&full=1HONG KONG</span>, <span class"xn-chron">Oct. 3, 2012</span> /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in <span class"xn-location">China</span>, announced that it has successfully completed the previously announced <span class"xn-money">$50 million</span> convertible note financing with Golden Meditech...Wed, 03 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274531&full=1Munich, Germany, October 1, 2012 / B3C newswire / - Definiens AG, the leader in Image Analysis for Digital Pathology, today announced that it has closed a private round of financing of 10 million. The financing was led by new investor Gilde Healthcare Partners, a transatlantic investment firm with 450 million under management, focusing on the private healthcare sector. Existing investors, including...Mon, 01 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274595&full=1<div id"releaseBody"><p>MELBOURNE, AUSTRALIA--(Marketwire - October 01, 2012) - <b> Prana Biotechnology Limited</b> (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerPRAN">PRAN</a>) (ASX: PBT) today announced that it has raised A$6.0 million (approx.) through a placement of 32,500,000 ordinary fully paid shares (equivalent to 3.25 million NASDAQ listed ADRs) at a price of A$0.1...Mon, 01 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274693&full=1Paris, October 1, 2012 - Biophytis, a research company in health and nutrition focusing on metabolic disorders and age-related diseases, announces today that it has raised EUR two million (USD 2.6M) in a B round. Metabrain Research, a spin-off of Merck Serono based in Chilly-Mazarin (south of Paris) joined existing investors Seventure partners and CM-CIC Capital Prive in this round. </p><p>This...Mon, 01 Oct 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120924September 24, 2012 -- As the first multinational company to open a research centre in China in 1997, Novo Nordisk now reaffirms its long-term commitment to the country by investing an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing.</p><p>The new 12,000m2 centre will make it possible to increase the number of science employees from the current 13...Mon, 24 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273920&full=1September 24th, 2012 -- The North West Fund for Biomedical, the 25million fund managed by SPARK Impact, has invested 350,000 into a drug discovery company which could lower the cost of inventing new medicines.</p><p>Molplex Ltd has developed automated decision making systems using predictive chemistry and biology software which incorporate critical decisions made by drug development professionals...Mon, 24 Sep 2012 12:00:00 AM GMT